The CTSV Antibody (CAB7662) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody, raised in rabbits, exhibits high reactivity with human samples and is validated for use in Western blot applications.Cathepsin L2 is known to be dysregulated in a variety of diseases, including cancer, cardiovascular diseases, and autoimmune disorders, making it a promising target for therapeutic interventions.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Human, Mouse, Rat samples.
Product Name:
CTSV Antibody
SKU:
CAB7662
Size:
20μL, 100μL
Reactivity:
Human, Mouse, Rat
Conjugate:
Unconjugated
Immunogen:
Recombinant protein (or fragment).This information is considered to be commercially sensitive.
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
CTSU, CATL2, CTSL2, CTSV
Positive Sample:
HeLa, A-549, Mouse liver, Rat liver
Cellular Localization:
Lysosome.
Calculated MW:
37kDa
Observed MW:
37kDa
The protein encoded by this gene, a member of the peptidase C1 family, is a lysosomal cysteine proteinase that may play an important role in corneal physiology. This gene is expressed in colorectal and breast carcinomas but not in normal colon, mammary gland, or peritumoral tissues, suggesting a possible role for this gene in tumor processes. Alternatively spliced variants, encoding the same protein, have been identified.
Purification Method
Affinity purification
Gene ID
1515
RRID
AB_2769081
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of various lysates using CTSV Rabbit pAb (CAB7662) at 1:1000 dilution. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 30s.
